These studies highlight that germline genetic variations in patients with cancer, such as Fc-γR polymorphisms, could contribute to effective immune activation, including efficient Treg depletion with anti–CTLA-4 therapies that would be relevant to assess in ongoing and future clinical trials testing this immunotherapy in patients with GBM. This evidence concerns the gene CTLA4 and glioblastoma.